The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO Italy 2022 | Using BCMA-targeting agents in earlier lines of treatment for multiple myeloma
In this video, Hans Lee, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of BCMA-targeting agents in earlier lines of treatment in relapsed/refractory (R/R) multiple myeloma. Dr Lee also highlights the impact that this may have on subsequent treatment with CAR-T therapy, and the need to conduct more research to better understand mechanisms of resistance and how to best sequence these therapies. This interview took place at The 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
